These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34620404

  • 1. On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy.
    Lee HH, Lee H, Cho SMJ, Kim DW, Park S, Kim HC.
    J Am Coll Cardiol; 2021 Oct 12; 78(15):1485-1495. PubMed ID: 34620404
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults.
    Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, Kim HC.
    Circulation; 2020 Jun 02; 141(22):1778-1786. PubMed ID: 32479205
    [Abstract] [Full Text] [Related]

  • 3. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, Carson TY, Tamariz L, Ghazi L, Cho ME, Shapiro BP, He J, Fine LJ, Lewis CE, SPRINT Research Study Group.
    Circulation; 2017 Aug 01; 136(5):440-450. PubMed ID: 28512184
    [Abstract] [Full Text] [Related]

  • 4. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.
    Tajeu GS, Booth JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O'Brien EC, Oparil S, Ravenell J, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntner P.
    Circulation; 2017 Aug 29; 136(9):798-812. PubMed ID: 28634217
    [Abstract] [Full Text] [Related]

  • 5. Optimal Target Blood Pressure and Risk of Cardiovascular Disease in Low-Risk Younger Hypertensive Patients.
    Kwon CH, Kang J, Cho A, Chang Y, Ryu S, Sung KC.
    Am J Hypertens; 2019 Aug 14; 32(9):833-841. PubMed ID: 31045225
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg.
    Heimark S, Mehlum MH, Mancia G, Søraas CL, Liestøl K, Wachtell K, Larstorp AC, Rostrup M, Mariampillai JE, Kjeldsen SE, Julius S, Weber MA.
    Hypertension; 2023 Aug 14; 80(8):1739-1748. PubMed ID: 37350267
    [Abstract] [Full Text] [Related]

  • 8. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
    Rodriguez CJ, Swett K, Agarwal SK, Folsom AR, Fox ER, Loehr LR, Ni H, Rosamond WD, Chang PP.
    JAMA Intern Med; 2014 Aug 14; 174(8):1252-61. PubMed ID: 24935209
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?
    Mohebi R, Mohebi A, Ghanbarian A, Momenan A, Azizi F, Hadaegh F.
    J Am Soc Hypertens; 2014 Jul 14; 8(7):491-7. PubMed ID: 25064771
    [Abstract] [Full Text] [Related]

  • 11. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
    Johnson K, Oparil S, Davis BR, Tereshchenko LG.
    J Am Heart Assoc; 2019 Apr 16; 8(8):e011961. PubMed ID: 30943832
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S.
    Lancet; 2017 Jun 03; 389(10085):2226-2237. PubMed ID: 28390695
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE (Losartan Intervention for Endpoint Reduction) Study Group.
    JAMA; 2002 Sep 25; 288(12):1491-8. PubMed ID: 12243636
    [Abstract] [Full Text] [Related]

  • 16. Residual Cardiovascular Risk in Individuals on Blood Pressure-Lowering Treatment.
    Lieb W, Enserro DM, Sullivan LM, Vasan RS.
    J Am Heart Assoc; 2015 Nov 20; 4(11):. PubMed ID: 26588944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C, Chen K, Cornelius V, Tomeny E, Wang Y, Yang X, Yuan X, Qin R, Yu D, Wu Z, Wang D, Chen T.
    PLoS Med; 2021 Mar 20; 18(3):e1003515. PubMed ID: 33661907
    [Abstract] [Full Text] [Related]

  • 20. Interrelations Between Hypertension and Electrocardiographic Left Ventricular Hypertrophy and Their Associations With Cardiovascular Mortality.
    Cao X, Broughton ST, Waits GS, Nguyen T, Li Y, Soliman EZ.
    Am J Cardiol; 2019 Jan 15; 123(2):274-283. PubMed ID: 30390988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.